High dose methotrexate followed by citrovorum factor reversal in patients with advanced cancer
- 1 April 1979
- Vol. 43 (4) , 1177-1182
- https://doi.org/10.1002/1097-0142(197904)43:4<1177::aid-cncr2820430403>3.0.co;2-r
Abstract
High dose methotrexate followed by citrovorum factor reversal has been utilized in twenty‐six patients with advanced cancer. Four of 10 patients with head and neck cancer had an objective response. One of 7 patients with metastatic osteosarcoma to the lungs had stabilization with twenty treatments over 23 months. One patient with acute lymphocytic leukemia developed marrow aplasia but did not attain remission. The regimen was well tolerated when meticulous attention was paid to hydration, urine alkalinization, renal function and third space fluid accumulation. Life‐threatening or lethal toxicity was encountered when these phenomena were not scrupulously observed.This publication has 5 references indexed in Scilit:
- Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas).Prolonged Unmaintained RemissionsCancer, 1976
- New Approaches to Cancer Chemotherapy with MethotrexateNew England Journal of Medicine, 1975
- Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic SarcomaNew England Journal of Medicine, 1974
- Recent advances in the chemotherapy of metastatic osteogenic sarcomaCancer, 1972
- Continuous infusion of methotrexate in children with acute leukemiaCancer, 1967